Antibody drug conjugate programs (ADCs) are growing fast in oncology, combining selectivity with high potency.

A recent case has shown that, the body can have an unexpected systemic immune response after a Botox procedure. This reaction ...

Learn how KMA and LMA represent a breakthrough in treatment approaches for multiple myeloma and related disorders.

New research suggests the skin does much more than detect damage or keep pathogens out. By tracing how skin cells respond to ...

Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levels IMP761 data ...

Pasteur, Vallery Radot, Halpen and Haltzer 1 assert that an anti-histaminic-inhibited shock has no tachiphylactic action ; more precisely, rabbits protected from a shock by an anti-hystaminic died of ...

TG Therapeutics, Inc. (“TG” or “the Company”), (NASDAQ: TGTX), today announced that it has entered into a new five-year, $750 million senior secured credit facility with funds managed by Blue Owl ...

A collaborative effort led by Professor Wanli Liu 's team at Tsinghua University has uncovered a sophisticated mechanism by ...

California biotech Kali Therapeutics has snagged its first major pharma partner, Sanofi, which is committing $180 million in ...

The 2026 PSMA & Beyond conference featured a targeting the cell surface session and presentation by Dr. Tanya Dorff discussing antibody drug conjugates and BiTEs and their role in prostate cancer. Dr.